文献速递心力衰竭与心肌病

肥胖相关人体测量指标与HFmrEF/HFpEF临床结局:5项随机试验参与者水平汇总分析

Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.
PubMed 文献 · J Am Coll Cardiol · 2025-08-27

该研究汇总5项国际随机试验中HFmrEF/HFpEF成人的参与者水平数据,评估BMI、腰围(WC)与腰高比(WHtR)与心衰及死亡结局的关联。结果显示BMI呈J/U形关联,而WHtR升高与心衰和死亡事件风险呈线性相关,且在BMI<30 kg/m2者中多数仍存在腹部肥胖。

要点

  • WHtR升高与心衰及死亡事件风险呈线性相关,独立于BMI。
  • BMI<30 kg/m2者中89%存在腹部肥胖,WHtR可补充风险分层。
  • BMI与WHtR同时升高者心血管死亡或心衰住院率高于单一指标升高者。

核心结论

  • 在HFmrEF/HFpEF人群中,WHtR升高与心衰和死亡事件风险呈线性相关,独立于BMI。
  • BMI与临床结局呈复杂J形和U形关联,不宜作为定义肥胖的唯一指标。

研究设计与样本

  • 5项国际随机试验的参与者水平汇总分析,纳入HFmrEF/HFpEF成人。
  • 基线BMI可评估21,479例,WC和WHtR可评估7,827例。

主要发现

  • 基线46%参与者BMI≥30 kg/m2,95%存在WC或WHtR升高。
  • BMI<30 kg/m2者中89%存在腹部肥胖,老年和女性更常见。
  • 性别(Pinteraction=0.003)和种族(Pinteraction=0.046)修饰BMI与WHtR的关联。
  • 年轻参与者中BMI或WHtR与心血管死亡或心衰住院的关联最陡(Pinteraction<0.001)。
  • 独立于WHtR,较高BMI与心衰住院相关。

关键数值与推荐

  • BMI<30 kg/m2者中89%存在腹部肥胖。
  • BMI与WHtR交互:性别Pinteraction=0.003,种族Pinteraction=0.046。
  • 年龄交互:BMI或WHtR与心血管死亡或心衰住院Pinteraction<0.001。

临床怎么用

  • 在HFmrEF/HFpEF中除BMI外应评估WC或WHtR以识别腹部肥胖。
  • WHtR可增强BMI之外的风险分层,尤其对老年和女性患者。

局限性

  • WC和WHtR仅在7,827例中可评估,样本少于BMI可评估者。
  • 为汇总分析,非前瞻性设计,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) and is associated with increased risk of disability and death. OBJECTIVES: The purpose of this study is to explore the association between different adiposity-related anthropometrics and clinical outcomes in this population. METHODS: In this participant-level pooled analysis of 5 international randomized trials that enrolled adults with HFmrEF/HFpEF, the association between adiposity-related anthropometrics (body mass index [BMI], waist circumference [WC], and waist-to-height ratio [WHtR]) and heart failure (HF) and mortality outcomes was evaluated, overall and by age and sex. Independent and combined associations between BMI and/or WHtR and outcomes were also assessed. RESULTS: At baseline, BMI was available in 21,479 participants, and WC and WHtR were available in 7,827. Overall, 46% had BMI ≥30 kg/m2 and 95% had elevated WC or WHtR. Among those with BMI <30 kg/m2, 89% had excess abdominal adiposity, especially older and female participants. Sex (Pinteraction = 0.003) and race (Pinteraction = 0.046) modified the association between BMI and WHtR, such that women vs men had higher WHtR at higher BMI, and Asian and Black participants had higher WHtR at lower BMI. Although BMI exhibited complex J- and U-shaped associations with clinical outcomes, higher WHtR was linearly associated with increased risk of HF and mortality events. Younger participants exhibited the steepest associations between BMI or WHtR and cardiovascular death or HF hospitalization (Pinteraction <0.001 for both). Independent of BMI, higher WHtR was associated with adverse outcomes. Independent of WHtR, higher BMI was associated with HF hospitalization. Participants with elevated BMI and WHtR experienced higher rates of cardiovascular death or HF hospitalization vs those with elevated BMI or WHtR alone. CONCLUSIONS: These data from 5 large-scale HFmrEF/HFpEF clinical trials further question the utility of BMI as the sole measure to define obesity. WC or WHtR assessment identifies a substantial number of individuals with abdominal obesity despite BMI <30 kg/m2, and may enhance risk stratification beyond BMI alone in HFmrEF/HFpEF. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213; Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711; Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve] (NCT00095238); Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Preserved] (NCT00634712).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ostrominski, Højbjerg Lassen, Butt, et al. Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. J Am Coll Cardiol. 2025. PMID: 40864017. doi:10.1016/j.jacc.2025.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。